Method for promoting improvement of antiviral character of fish

The CRISPR/Cas9 technology mutates the cox17 gene to construct the cox17 mutant fish, which significantly improved its resistance to Spring Viraemia of Carp Virus, solved the problem of insufficient antiviral traits in fish, and achieved stronger antiviral effects.

CN118956866AActive Publication Date: 2024-11-15HUAZHONG AGRI UNIV

Patent Information

Application Number
CN202411025101.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-15
Estimated Expiration
2044-07-29

AI Technical Summary

Technical Problem

Fish are inadequate in resistance to viruses, which leads to susceptibility to viral diseases. The existing technology is difficult to effectively improve their antiviral traits.

Method used

Through CRISPR/Cas9 gene editing technology, cox17 gene mutation was constructed, and cox17 mutant fish was injected into fish embryos using cox17-gRNA and Cas9 mRNA to screen individuals with cox17 gene mutant to enhance their antiviral ability.

Benefits of technology

The cox17 mutant fish showed lower lethality, stronger antiviral activity, higher IFN1 and IFN3 gene promoters that drive dual luciferase activity and irf family mRNA expression when infected with Spring Viraemia of Carp Virus (SVCV). Upregulation reduces the amount of residual viruses in the body and enhances the ability to kill viruses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118956866A_ABST
    Figure CN118956866A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of COX17 genes, in particular to a method for promoting improvement of antiviral characters of fishes. The embodiment finds that cox17 gene mutation fish can obtain resistance to virus stress, so that solid technical support and wide application prospect are provided for improvement and breeding of anti-virus fish.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of cox17 gene technology, and specifically to a method for promoting the improvement of antiviral traits in fish. Background Art

[0002] COX (cytochrome c oxidase, also known as complex IV or CcO) is a transmembrane protein located on the mitochondrial membrane and is present in the mitochondria of bacteria and eukaryotes (Wu et al., 2016). The functions of COX include receiving electrons from cytochrome c, transferring them to oxygen molecules, and completing oxygen reduction by producing water molecules. In addition, COX transports four protons across the membrane, thereby contributing to the formation of the proton electrochemical potential energy difference across the membrane, providing energy for the synthesis of adenosine triphosphate (ATP) by ATP synthase (Baker et al., 2017; Ducker and Rabinowitz, 2017).

[0003] COX17 (Cytochrome c oxidase assembly homolog 17) is a type of COX, containing 69 amino acids and 6 cysteine ​​residues that can bind metal ions. COX17 is a soluble copper-binding protein of approximately 7 kDa in length. COX17 is involved in the assembly and copper metallization of cytochrome c oxidase (Garcia et al 2016; Soto et al 2012), and is involved in regulating the distribution and content of copper in mitochondria (Heaton et al 2001). COX17 has recently been found to be involved in the assembly of the mitochondrial contact site and cristaeorganizing system (MICOS). The main function of MICOS is to establish and maintain the proper mitochondrial inner membrane structure and connect the mitochondrial outer membrane, and the interaction between COX17 and MICOS is regulated by copper ions (Ge et al 2022).

[0004] Some developmental and physiological characteristics of COX17 mutants have been revealed in Arabidopsis (Garcia et al 2016), yeast (Beers et al 1997), and mammalian cells (Heaton et al 2001). In addition, COX17 is also associated with some blood diseases, such as acute myeloid leukemia (Singh et al., 2020). Studies have found that the mitochondrial metal carrier protein COX17 can reduce the DNA methylation level of AML cells, promote the differentiation of AML cells, and inhibit the proliferation of AML stem cells (Singh et al 2020). Recent studies have shown that the loss of COX17 or its non-acetylated mutations leads to defects in mitochondrial structure, including breakage, reduced cristae density, and impaired integrity of mitochondrial electron transport chain complex IV, and acetylation mimics of COX17 can rescue these defects (Guhathakurta et al 2023). Summary of the invention

[0005] The inventors of the present application creatively discovered that fish with cox17 gene mutations can acquire resistance to viral stress, thereby providing solid technical support and broad application prospects for the improvement and breeding of virus-resistant fish.

[0006] To this end, the embodiments of the present application disclose at least the following technical solutions:

[0007] In the first aspect, the embodiment discloses cox17-gRNA, which is used in a CRISPR / Cas9 kit for targeted editing of the cox17 gene. The nucleotide sequence of the cox17-gRNA is as shown in SEQ ID NO:1.

[0008] In a second aspect, the embodiment discloses a primer pair for synthesizing the cox17-gRNA described in the first aspect. The primer pair includes a DNA molecule as shown in SEQ ID NO: 2 and SEQ ID NO: 3.

[0009] In a third aspect, the embodiments disclose a CRISPR / Cas9 kit targeting the cox17 gene, comprising Cas9 mRNA as shown in SEQ ID NO: 29 and cox17-gRNA as shown in SEQ ID NO: 1.

[0010] In a fourth aspect, the embodiment discloses a method for constructing a cox17 gene mutant fish. The method comprises: synthesizing Cas9 mRNA as shown in SEQ ID NO: 29 and cox17-gRNA as shown in SEQ ID NO: 1; injecting the Cas9 mRNA and the gRNA into the embryo of the fish; culturing the embryo into F0 generation fish; and screening the cox17 gene mutant fish from the F0 generation fish or the offspring of the F0 generation fish.

[0011] In the fifth aspect, the embodiments disclose the use of the cox17-gRNA described in the first aspect, the primer pair described in the second aspect, or the kit described in the third aspect in constructing antiviral fish. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 This is a schematic diagram of the cox17 gene mutation target.

[0013] Figure 2 In the case of the same infection with Spring Viraemia of Carp Virus (SVCV), cox17 - / - Zebrafish have a lower mortality rate and are more resistant to viruses.

[0014] Figure 3 In the case of the same SVCV infection, cox17 - / - The dual luciferase activity driven by the zebrafish IFN1 and IFN3 gene promoters was enhanced, suggesting that cox17 - / - Enhanced antiviral activity in zebrafish.

[0015] Figure 4 In the case of the same SVCV infection, cox17 - / - The expression of zebra antiviral irf (interferon regulator factor) family genes mRNA level was upregulated, indicating that cox17 - / - Zebrafish have a stronger ability to resist viruses.

[0016] Figure 5 In the case of the same SVCV infection, cox17 - / - There are fewer residual viruses in zebrafish and they have a stronger ability to kill viruses.

[0017] Figure 6 In the case of the same SVCV infection, cox17 - / - Cyprinus carpio epithelioma cells (EPCs) infected with zebrafish tissue homogenate produced less cytopathic effect (CPE), indicating that cox17 - / - Zebrafish have a stronger ability to kill viruses. DETAILED DESCRIPTION

[0018] In order to make the purpose, technical scheme and advantages of the present application clearer, the present application is further described in detail in conjunction with the embodiments below. It should be understood that the specific embodiments described herein are only used to explain the present application and are not used to limit the present application. The reagents not described separately in detail in the present application are all conventional reagents and can be obtained from commercial channels; the methods not described in detail are all conventional test methods and can be obtained from the prior art.

[0019] The wild-type zebrafish (Danio rerio) and mutants required in the examples were raised in the fish house of the College of Fisheries of Huazhong Agricultural University under the following culture conditions: water temperature of 28.5±0.5°C, light and dark time of 14h and 10h respectively, and Artemia larvae were fed twice a day.

[0020] cox17-gRNA and its synthesis

[0021] In the embodiment, based on the cox17 cDNA sequence (gene ID: 447914), the first 2 / 3 region of the CDS of the gene and after ATG were selected to design cox17-gRNA, as shown in SEQ ID NO: 1.

[0022] Primer pair cox17-gRNA-F and cox17-gRNA-R used to synthesize cox17-gRNA.

[0023] cox17-gRNA-F: GTAATACGACTCACTA TAGGCTTCACCTGCAGCGATAGgttttagagctagaaatagc, the underline is the nucleotide sequence of the T7 promoter, and the lowercase is the homologous sequence to the inherent conservative sequence of gRNA, as shown in SEQ ID NO: 2,

[0024] The cox17-gRNA-R sequence is complementary to the 3' end of the plasmid pT7-gRNA (Addgene, Catalog #46759) and is used to synthesize cox17-gRNA. cox17-gRNA-R: AAAAGCACCGACTCGGTGCC, as shown in SEQ ID NO:3.

[0025] The embodiment also discloses a method for synthesizing cox17-gRNA. The method comprises:

[0026] 1) Synthesize the PCR product of cox17-gRNA using pT7-gRNA as a template. The pT7-gRNA plasmid contains a conserved sequence of the gRNA transcription template (SEQ ID NO: 4). The cox17-gRNA PCR product synthesized using the pT7-gRNA plasmid as a template can form a gRNA hairpin structure after in vitro transcription, thereby enabling the Cas9 protein to perform a cleavage function in the cell.

[0027] Cox17-gRNA-F and cox17-gRNA-R are formulated into a cox17-gRNA synthesis system. The cox17-gRNA synthesis system contains 4 μL pT7-gRNA (1 ng / uL), 100 μL 2×Mix, 4 μL cox17-gRNA-F, and 4 μL cox17-gRNA-R in 200 μL. The reaction steps for the cox17-gRNA synthesis include: pre-denaturation at 94°C for 3 min, 30 cycles (denaturation at 94°C for 30 s, annealing at 60°C for 30 s, extension at 72°C for 10 s), and extension at 72°C for 5 min.

[0028] 1 μL of the PCR product obtained in step 1) was subjected to agarose gel electrophoresis detection and then purified and recovered using a PCR clean kit; in vitro transcription was performed using a Thermo TranscriptAid T7 High Yield Transcription Kit, and the transcription system is shown in Table 1.

[0029] Table 1

[0030] 5xTranscriptAidReactionBuffer 4μL ATP / CTP / GTP / UTPmix 8μL (2μL / each) TranscriptAidEnzymeMix 2μL PCR products 1 μg DEPC-treated water up to 20 μL

[0031] 2) Harvesting cox17-gRNA from in vitro transcripts

[0032] The in vitro transcription reaction system was mixed and centrifuged, sealed and incubated in a 37°C water bath for 2 hours; 1μL DNase was added at 37°C for 15 minutes to remove the DNA template; 1μL ETA was added at 60°C for 10 minutes to terminate the reaction; 30μL DEPC water and 30μL LiCl were added, mixed and precipitated at -80°C for 4 hours; centrifuged at 4°C and 14000g for 10 minutes; the supernatant was discarded, 1mL 70% ethanol was added for washing, and the supernatant was centrifuged at 4°C and 14000g for 10 minutes; the previous step was repeated; after discarding the supernatant, it was dried at room temperature, 20μL RNase-free water was added for dissolution, 1μL was taken to measure the RNA concentration and quality using the NanoDrop 2000 nucleic acid quantification instrument, diluted to 80ng / μL, and placed at -80°C for standby use after aliquoting, which is a solution containing 80ng / μL cox17-gRNA.

[0033] Cas9 mRNA and its synthesis

[0034] The embodiment also discloses Cas9 mRNA, whose nucleotide sequence is shown in SEQ ID NO:29.

[0035] The embodiment also discloses a method for synthesizing Cas9 mRNA. The method comprises: digesting pT3TS-nCas9n plasmid (Addgene, Catalog #46757) with XbaI; recovering the linearized fragment of pT3TS-nCas9n plasmid from the digested product; in vitro transcribing the linearized fragment of pT3TS-nCas9n plasmid; and obtaining Cas9 mRNA from the in vitro transcript.

[0036] Table 2 shows the reaction system for in vitro transcription of the linearized fragment of the pT3TS-nCas9n plasmid, in which the Cas9 mRNA was transcribed in vitro using Ambion's MAXIscript T3 Kit. The in vitro transcription reaction system was mixed and centrifuged, sealed and placed in a 37°C water bath for 2 hours; 1 μL DNase was added at 37°C for 15 minutes to remove the DNA template; 1 μL ETA was added at 60°C for 10 minutes to terminate the reaction.

[0037] Table 2

[0038] ReactionBuffer 2μL 2xNTP / CAP 10μL TemplateDNA 1 μg T3EnzymeMix 1μL DEPC-treated water up to 20 μL

[0039] In some embodiments, the step of obtaining Cas9 mRNA from the in vitro transcript includes: adding 30 μL DEPC water and 30 μL LiCl to the in vitro transcript (20 μL reaction system), mixing and precipitating at -80°C for 4 hours; centrifuging at 4°C and 14000g for 10 minutes; discarding the supernatant, adding 1 mL 70% ethanol for washing, and centrifuging at 4°C and 14000g for 10 minutes. Repeat the previous step, discard the supernatant, dry at room temperature, add 20 μL RNase-free water to dissolve, take 1 μL NanoDrop 2000 nucleic acid quantifier to measure RNA concentration and quality, dilute to 500 ng / μL, and place at -80°C for standby use after aliquoting, which is a solution containing 500 ng / μL Cas9 mRNA.

[0040] CRISPR / Cas9 gene editing kit targeting cox17 gene and method for constructing cox17 gene mutant fish

[0041] The embodiment discloses a CRISPR / Cas9 gene editing kit targeting the cox17 gene, comprising Cas9 mRNA as shown in SEQ ID NO:29 and cox17-gRNA as shown in SEQ ID NO:1.

[0042] In some embodiments, the gene editing kit includes a 500 ng / μL Cas9 mRNA solution and an 80 ng / μL cox17-gRNA solution.

[0043] The embodiment discloses a method for constructing a cox17 gene mutant fish. The method comprises: synthesizing Cas9 mRNA as shown in SEQ ID NO:29 and cox17-gRNA as shown in SEQ ID NO:1; mixing the Cas9 mRNA and the cox17-gRNA and injecting them into the embryo of the fish; culturing the embryo into F0 generation fish; and screening the cox17 gene mutant fish from the F0 generation fish or the offspring of the F0 generation fish.

[0044] In some embodiments, 500 ng / μL Cas9 mRNA and 80 ng / μL cox17-gRNA are mixed in equal volumes, and the mixture is injected into zebrafish embryos of one cell cycle using a Picoliter Microinjector (Warner, USA); the zebrafish embryos are cultured in a 28°C light-controlled incubator with methylene blue culture medium, and the fry are placed in the system until they grow into F0 adult fish; the F0 adult fish are mated with wild-type zebrafish, and F1 embryos are collected; the F1 embryos are cultured to adult fish, and zebrafish with cox17 deficiency are screened from the F1 adult fish.

[0045] In some embodiments, zebrafish embryos injected with Cas9 mRNA and cox17-gRNA are cultured for 24 hours and then F0 generation embryos are screened.

[0046] In some embodiments, the screening step includes: lysing the embryos to be screened with 50mM NaOH at 95°C for 20min, balancing the pH with pH 8.050mM Tris-HCl, PCR amplifying the balanced solution with F1 (SEQ ID NO: 5) and R1 (SEQ ID NO: 6), performing agarose gel electrophoresis on the PCR products, collecting the electrophoresis bands to determine that the PCR products are correct, and then sequencing them, and opening the sequencing results in SnapGene software for sequence alignment. If the sequencing results have double peaks near the target point, it proves that the target point is effective, and the F0 embryos injected in the same batch corresponding to the effective target point are cultured to obtain the F0 generation adult fish with cox17 mutations.

[0047] Screening of F1 adult fish carrying cox17 mutation

[0048] The embodiment also provides a method for screening F1 adult fish carrying cox17 mutation. The method comprises: mating F0 adult fish with cox17 mutation with wild-type fish to breed F1 individuals, raising F1 embryos to 1 to 2 months of age; taking tail fin tissue, lysing it with 50mM NaOH at 95°C for 20 minutes, balancing the pH with pH 8.050mM Tris-HCl, using F1 and R1 as primers to PCR amplify the balanced solution, performing agarose gel electrophoresis on the PCR products, collecting the electrophoresis bands for sequencing, and screening F1 adult fish with cox17 mutation.

[0049] The remaining PCR product was purified and recovered by a PCR purification kit, and then connected to the pMD18-T (Takara, Catalog #6011) vector, transformed, and single colonies were selected for colony PCR amplification, and the amplified products were sent to Qingke Biotech for sequencing. According to the sequencing results, the sequence of each individual was analyzed, compared with the wild normal gene sequence, and the mutation target sequence was analyzed. Each mutant type was guaranteed to exist in both males and females, and males and females with the same mutation type were mated to obtain F2 embryos.

[0050] Screening of F2 adult fish carrying cox17 mutation

[0051] The embodiment also provides a method for screening F2 adult fish carrying cox17 mutation. The method comprises: mating and breeding F2 generation embryos with the F1 male and female adult fish with cox17 mutation; raising the F2 embryos to adult fish; taking tail fin tissue and lysing it with 50mM NaOH at 95°C for 20min, balancing the pH with pH 8.050mM Tris-HCl, using F1 and R1 as primers to PCR amplify the balanced solution, performing agarose gel electrophoresis on the PCR products, collecting the electrophoresis bands for sequencing, and screening F2 adult fish with cox17 mutation.

[0052] like Figure 1 As shown, the target sequence of the wild-type cox17 gene shown in SEQ ID NO: 7 mutated to the sequence shown in SEQ ID NO: 8, and a frameshift mutation occurred.

[0053] SVCV infection test

[0054] Some test cases tested the cox17 mutant zebrafish embryos and wild-type (control) zebrafish embryos constructed in the above steps, and tested the antiviral effect of cox17 mutant zebrafish embryos and larvae against SVCV by SVCV infection. The specific test steps include:

[0055] 1. Preparation of SVCV virus solution

[0056] Carp epithelioma cells (EPC, ATCC: CRL-2872) were subcultured into six-well plates, and carp spring viremia virus solution (SVCV, ATCC: VR-1390) was inoculated when the cell coverage was about 95%. Place in a 28°C, 5% CO2 incubator for 2 hours to allow the virus to fully contact and infect the cells. Re-add complete medium of DMEM + 10% FBS. Observe the cells regularly to see if they have lesions. When the cells are observed to become round or the attached cells fall off, freeze and thaw repeatedly to collect the virus solution. The amplified carp spring viremia virus obtained was placed at -80°C for later use.

[0057] 2. Titer determination of SVCV virus fluid

[0058] EPC cells were passaged to 96-well plates, and the virus was inoculated when the EPC cells covered the entire well. The virus was inoculated with 100 μL of 10-fold gradient dilutions, with 8 parallels per group. The virus was allowed to infect for 2 hours, and the virus dilution was gently mixed every 30 minutes to allow the virus to fully contact and infect the cells. The virus dilution was discarded with a pipette, and 100 μL of complete medium containing DMEM + 10% FBS was added to each well, and then placed in a cell culture incubator for 3 days. The number of wells that formed plaques in each group was measured, and the number of wells was calculated according to the TCID 50 Calculate the virus titer.

[0059] 3. SVCV infection of zebrafish embryos

[0060] 1.5×10 6 TCID 50 / mL, a total of 10mL, add 30 zebrafish embryos for infection, count the mortality of zebrafish embryos or fry every 12 or 24 hours, and draw a line graph of zebrafish fry mortality. Among them, lethality (%) = 100% × (number of deaths per repetition / total number of repetitions (30)). The average lethality (%) is the average of the lethality measured repeatedly for each group.

[0061] The results are as follows Figure 2 As shown, 24 hours after SVCV infection, the mortality rate of cox17 mutant zebrafish was not significantly different from that of wild-type zebrafish; however, 36 hours after SVCV infection, the mortality rate of cox17 mutant zebrafish was significantly lower than that of wild-type zebrafish, and 96 hours after virus infection, the mortality rate of cox17 mutant zebrafish was significantly lower than that of wild-type zebrafish. The above results suggest that the mortality rate of cox17 mutant zebrafish is significantly reduced after being stressed by SVCV virus, and the cox17 mutant zebrafish has significantly enhanced its resistance to the virus.

[0062] Dual luciferase activity analysis driven by IFN1 and IFN3 gene promoters and qRT-PCR of antiviral related genes

[0063] Some test cases also performed dual luciferase activity analysis driven by the IFN1 and IFN3 gene promoters and qRT-PCR detection of antiviral-related genes on cox17 mutant zebrafish embryos and wild-type zebrafish embryos after SVCV virus stress.

[0064] 1. Dual luciferase activity analysis

[0065] (1) Construction of recombinant plasmids pGL3-IFN1 and pGL3-IFN3

[0066] The promoter sequence of the IFN1 gene was amplified by PCR using IFN1-F (GGGGTACCTCAGCAAAAGCGAACCTTCTGTAGA, SEQ ID NO: 30) and IFN1-R (CCCTCGAGGCTCAAGAGAAAGTTTCAGAGACAT, SEQ ID NO: 31) as a primer pair and zebrafish DNA as a template.

[0067] The promoter sequence of the IFN3 gene was amplified by PCR using IFN3-F (CGGGGTACCACTAGGGTGCTGATTTTGA, SEQ ID NO: 32) and IFN3-R (CCTCGAGACTATACATTACCAGGTTAATTATG, SEQ ID NO: 33) as a primer pair and zebrafish DNA as a template.

[0068] The amplified product was purified using an AxyPrep DNA purification kit (AP-GX-250, Axygen, USA), and the purified amplified product was enzymatically linked to the pGL3-Basic linearized vector (Addgene, Catalog #212936) using T4 DNA ligase (C301-01, Vazyme, China). The enzymatically linked product was transformed into Escherichia coli DH5a competent cells, positive colonies were screened, and recombinant plasmids pGL3-IFN1 and pGL3-IFN3 were extracted from the positive colonies. The recombinant plasmid pGL3-IFN1 is a plasmid carrying the promoter of the IFN1 gene (gene ID: 360134). The recombinant plasmid pGL3-IFN3 is a plasmid carrying the promoter sequence of the IFN3 gene (gene ID: 100126803).

[0069] (2) Recombinant plasmids pGL3-IFN1 and pGL3-IFN3 were used for dual luciferase activity analysis:

[0070] 1) pGL3-IFN1 and pGL3-IFN3 were mixed with Renilla (Addgene, Catalog #118016) at 25 ng / μL and 5 ng / μL, respectively, and then microinjected into zebrafish 1-cell embryos;

[0071] 2) Take 30 zebrafish embryos at 24 hpf and place them in a 1.5 mL EP tube. Add 400 μL of 1xPBS and grind. Centrifuge at 4°C and 1000 rcf for 5 min and discard the supernatant.

[0072] 3) Resuspend the cells in 1 mL PBS, filter with a 30-mesh filter cloth into a 2 mL EP tube, centrifuge at 4°C, 1000 rcf for 5 min, and discard the supernatant;

[0073] 4) Add 100 μL of 1× cell lysis buffer and treat at room temperature for 30 min. It can be used directly or stored in a -80°C refrigerator;

[0074] 5) Take 20 μL of the treated sample and place it in a 96-well plate, set up three replicates for each group, and place it on ice for testing;

[0075] 6) First add 15 μL of luciferase detection reagent LAR II, mix well and then test on the machine. Start reading for the first time. The result displayed is the value of firefly luciferase. Record the result;

[0076] 7) Take out the 96-well plate, quickly add 15 μL Stop&Glo reagent, mix well, read for the second time, the result displayed is the value of Renilla luciferase, record the result, firefly luciferase value / Renilla luciferase value, and standardize by Renilla luciferase activity;

[0077] Interferon IFN is a type of cytokine secreted by the body that can interfere with viral replication. When the body is infected by a virus, host cells release IFN to eliminate the pathogen. Figure 3 Through the dual luciferase activity detection test, it was found that 48 hours after SVCV virus infection of cox17 mutant zebrafish embryos and wild-type zebrafish embryos, the relative luciferase activity produced by cox17 mutant zebrafish embryos was higher. This shows that compared with wild-type zebrafish embryos, cox17 mutant zebrafish embryos have a positive regulatory effect on the IFN1 and IFN3 promoters, suggesting that the antiviral genes IFN1 and IFN3 of cox17 mutant zebrafish are significantly activated, and cox17 mutant zebrafish can significantly improve the fish's ability to resist viruses.

[0078] 2. Fluorescence quantitative PCR

[0079] Real-time fluorescence quantitative PCR reaction was performed using iQTM Green Supermix SYBR Green IDye (Bio-Rad), run in Bio-Rad CFX96TM Real-Time system. Prepare the reaction system shown in Table 4 for fluorescence PCR, the reaction steps include: 95℃10min; 95℃10s, 60℃20s, 72℃15s, 40 cycles; 65℃-95℃ heating 0.5℃ / time, collect fluorescence signal once every 6s; 30℃30s. The primer sequences are shown in Table 4, with the expression of 18s gene as the internal reference, and Methods The expression level of the target gene relative to the internal reference gene was calculated.

[0080] Table 3

[0081]

[0082] Table 4

[0083]

[0084]

[0085] Interferon regulatory factor irf can specifically bind to the IFN gene promoter and activate antiviral-related immune signals. In zebrafish, irf1, irf3, irf5, irf7, irf8, irf9 and irf11 can effectively stimulate the expression of zebrafish IFN1, irf1, irf7 and irf11 can effectively stimulate the expression of zebrafish IFN3, and irf2 and irf10 act as repressors to negatively regulate IFN gene transcription.

[0086] like Figure 4 As shown, after SVCV virus infection, the mRNA expression levels of irf1, irf3, irf5, irf7, irf9 and irf11 genes in cox17 mutant zebrafish embryos were significantly higher than those in wild-type zebrafish, and the mRNA expression levels of irf2 and irf10 genes were significantly lower than those in wild-type zebrafish. This indicates that cox17 mutant zebrafish can significantly activate antiviral-related immune signals after being stressed by SVCV virus, thereby improving virus resistance.

[0087] Anti-virus ability test

[0088] Some test cases also tested the antiviral ability of wild-type zebrafish embryos and cox17 mutant embryos. Specifically, they include:

[0089] (1) Collect 10 wild-type and cox17 homozygous mutant embryos at 48 hpi (Hours after infection) and 96 hpi after SVCV infection at 72 hpf zebrafish, rinse the embryos with sterile deionized water and place them in a 1.5 mL sterile EP tube. Add 500 μL of sterile triple-distilled water and use a grinding rod to grind the embryos evenly until there are no fragments.

[0090] (2) Pipette 100 μL of grinding solution into another 1.5 mL sterile EP tube, dilute to 0.5 mL with serum-free DMEM medium, discard the monolayer EPC cell culture supernatant, add virus diluent, and add 0.5 mL of virus diluent to each well of cells.

[0091] (3) The virus-infected EPC cells were placed back in a CO2 cell culture incubator and allowed to infect for 1-2 hours. During this period, the virus dilution solution was gently mixed every 30 minutes to allow the virus to fully contact and infect the cells.

[0092] (4) After virus infection, the unadsorbed free virus was aspirated and discarded with a pipette; the cytopathic effect of the virus on EPC cells was observed 24 h and 48 h after infection.

[0093] The results are as follows Figure 5 , Figure 6 As shown, after 24h and 48h of SVCV virus infection of cox17 mutant zebrafish embryos and wild-type zebrafish, it was observed that the EPC cells cultured in the tissue homogenate dilution corresponding to the cox17 mutant zebrafish embryos infected with SVCV virus had a lower lesion rate. This shows that in the same period of time, the cox17 mutant zebrafish embryos have less residual virus in the body, have a stronger ability to kill SVCV virus in the body, and have stronger antiviral ability.

[0094] The above is only a preferred specific implementation of the present application, but the protection scope of the present application is not limited thereto. Any changes or substitutions that can be easily conceived by any technician familiar with the technical field within the technical scope disclosed in the present application should be covered within the protection scope of the present application.

Claims

1. A gRNA used in a CRISPR / Cas9 kit for targeted editing of the cox17 gene, wherein the nucleotide sequence of the cox17-gRNA is as shown in SEQ ID NO:

1.

2. A primer pair for synthesizing the cox17-gRNA according to claim 1, wherein the primer pair comprises the DNA molecules shown in SEQ ID NO: 2 and SEQ ID NO:

3.

3. A CRISPR / Cas9 kit for targeted editing of the cox17 gene, comprising Cas9 mRNA as shown in SEQ ID NO:29 and cox17-gRNA as shown in SEQ ID NO:

1.

4. A method for constructing a cox17 gene mutant fish, the method comprising: Synthesize Cas9 mRNA as shown in SEQ ID NO:29 and cox17-gRNA as shown in SEQ ID NO:1; injecting the Cas9 mRNA and the gRNA into embryos of the fish; Cultivating the embryos into F0 generation fish; and The cox17 gene mutant fish is screened from the F0 generation fish or the offspring of the F0 generation fish.

5. The method according to claim 4, comprising: The zebrafish embryos injected with Cas9 mRNA and cox17-gRNA were cultured for 24 hours and then F0 embryos were screened; Extracting genomic DNA from the F0 generation embryos; PCR amplification was performed using the primer pair shown in SEQ ID NO: 5 and 6; The PCR products were subjected to agarose gel electrophoresis, and the electrophoresis bands were collected for sequencing, the F0 generation embryos with cox17 mutations were screened out, and the F0 generation adult fish with cox17 mutations were cultured.

6. The method according to claim 5, further comprising: The F0 generation adult fish with the cox17 mutation are mated with wild-type fish to produce F1 generation embryos; Raising the F1 generation embryos to F1 generation fry of 1 to 2 months old; Extracting genomic DNA from the F1 generation fry; PCR amplification was performed using the primer pair shown in SEQ ID NO: 5 and 6; The PCR products were subjected to agarose gel electrophoresis, and the electrophoresis bands were collected for sequencing to screen out F1 adult fish with cox17 mutations.

7. The method according to claim 6, further comprising: The cox17 mutant F1 adult fish are mated with wild-type fish to produce F2 generation embryos; Raising the F2 generation embryos to fry; Extracting genomic DNA from the F2 generation adult fish; PCR amplification was performed using the primer pair shown in SEQ ID NO: 5 and 6; The PCR products were subjected to agarose gel electrophoresis, and the electrophoresis bands were collected for sequencing to screen out F2 adult fish with cox17 mutations.

8. The method according to any one of claims 4 to 7, wherein the cox17 gene mutant fish is a homozygous mutant containing the sequence shown in SEQ ID NO:

8.

9. Use of the cox17-gRNA described in claim 1, the primer pair described in claim 2, or the CRISPR / Cas9 kit described in claim 3 in constructing antiviral fish.

Citation Information

Patent Citations

  • SgRNA combination for knocking out ddx18 gene of zebrafish and application of sgRNA combination

    CN116515825A

  • Application of fish cox17 gene in preparation of disease-resistant transgenic fish

    CN116555338A

  • METHOD OF CONSTRUCTING ZEBRAFISH notch1a MUTANTS

    US20190357507A1

Cited By

  • Plasmid for overexpressing IRF5 as well as construction method and application of plasmid

    CN119144653A

  • Method for improving crucian carp herpesvirus resistance of crucian carp

    CN119410716A